non-valvular atrial fibrillation
Cardiovascular · 2011–2013
10decisions
3medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| apixaban Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of stroke or systemic embolism. | Mar 2013 | Recommended | no section in document |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation who are inadequately controlled on warfarin or not suitable for… | Mar 2013 | Recommended | no section in document |
| dabigatran etexilate Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of developing stroke or systemic… | Jul 2012 | Recommended with restriction | no section in document |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) who are at risk of developing stroke or systemic embolism… | Mar 2012 | Not recommended | unclear |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) who are at risk of developing stroke or systemic embolism… | Mar 2012 | Recommended with restriction | unclear |
| apixaban prevention of stroke or systemic embolism in a patient with non-valvular atrial fibrillation who is at moderate-to-high risk of developing stroke or systemic… | Nov 2012 | Not recommended | no section in document |
| rivaroxaban Prevention of stroke or systemic embolism in a patient with non-valvular atrial fibrillation (NVAF) who is at risk of developing stroke or systemic embolism as… | Nov 2012 | Not recommended | no section in document |
| apixaban Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation (NVAF) at moderate-to-high risk. | Nov 2012 | Not recommended | no section in document |
| dabigatran etexilate Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of developing stroke or systemic… | Mar 2011 | Recommended | no section in document |
| dabigatran etexilate Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of developing stroke or systemic… | Mar 2011 | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.